1828-58-6

Usage

Uses

Used in Organic Synthesis:
3-bromo-4-hydroxy-5-nitrobenzonitrile is used as a starting material in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. Its unique functional groups allow for versatile chemical reactions, making it a valuable intermediate in the synthesis of a wide range of compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-bromo-4-hydroxy-5-nitrobenzonitrile is used as a key intermediate in the synthesis of specific drug molecules. Its presence in the molecular structure can impart desired properties to the final drug product, such as improved pharmacokinetics, enhanced efficacy, or targeted delivery.
Used in Agrochemical Industry:
3-bromo-4-hydroxy-5-nitrobenzonitrile is also utilized in the agrochemical industry as a precursor for the development of new pesticides or herbicides. Its functional groups can be modified to create compounds with specific modes of action, leading to the discovery of novel and effective agrochemicals.
Safety Precautions:
It is crucial to handle 3-bromo-4-hydroxy-5-nitrobenzonitrile with care, as it may pose health risks if ingested, inhaled, or comes into contact with the skin. Appropriate safety measures, including the use of personal protective equipment and adherence to proper handling protocols, should be taken when working with this chemical compound.

InChI:InChI=1/C7H3BrN2O3/c8-5-1-4(3-9)2-6(7(5)11)10(12)13/h1-2,11H

Upstream product

• 2315-86-8 3-bromo-4-hydroxybenzonitrile 
• 3272-08-0 4-hydroxy-3-nitrobenzonitrile 
• 1689-84-5 Bromoxynil 
• 767-00-0 4-cyanophenol 

Downstream Products

• 862730-24-3 3-amino-5-bromo-4-hydroxybenzonitrile 
• 1093395-68-6 methyl 4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)benzoate 
• 1093395-81-3 C₃₀H₂₈F₃N₅O₂ 
• 1093395-72-2 4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)-N-({1-[4-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methyl)benzamide 
• 1093395-96-0 C₂₉H₂₉N₅O₂ 
• 1292821-38-5 C₃₀H₂₈F₃N₅O₂ 
• 1093396-51-0 C₃₀H₃₁N₅O₃ 
• 1093395-89-1 4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)-N-({1-[4-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide 
• 1093395-88-0 methyl 6-[4-({[4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)benzoyl]amino} methyl)piperidin-1-yl]nicotinate 
• 1093395-87-9 methyl 6-[4-({[4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)benzoyl]amino}methyl)piperidin-1-yl]pyridine-2-carboxylate 
• 1292821-39-6 C₃₀H₂₉N₅O₄ 
• 1292821-40-9 C₂₉H₂₈N₆O₄ 
• 1093395-94-8 N-{[1-(5-bromopyridin-2-yl)piperidin-4-yl]methyl}-4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)benzamide 
• 1292821-41-0 C₃₂H₃₃N₅O₂ 

Relevant academic research and scientific papers

PRODRUGS OF 2-(4-(3-((4-AMINO-7-CYANO-IMIDAZO[2,1-F][1,2,4]TRIAZIN-2-YL)AMINO)PHENYL)PIPERAZ IN-1-YL)PROPANAMIDE DERIVATIVES AS CK2 INHIBITORS FOR THE TREATMENT OF CANCER

PRODRUGS OF IMIDAZOTRIAZINE COMPOUNDS AS CK2 INHIBITORS The invention provides pharmaceutically active compounds of formula (I) and prodrugs thereof. The formula (I) 2-(aminophenylamino)-4- amino-7-cyano-imidazo[2,1-f][1,2,4]triazine derivatives inhibit CK2 protein kinase activity, thereby making them useful for treating cancer, psoriasis and rheumatoid arthritis.

1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS

The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Scaffold design and advancement in HDLc-raising efficacy

The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Initial efforts aimed at engineering replacements for the aniline substructures in the benchmark molecule. Reversing the connectivity of the central aniline lead to a new class of 2-(4-carbonylphenyl)benzoxazoles. Structure-activity studies at the C-7 and terminal pyridine ring allowed for the optimization of potency and HDLc-raising efficacy in this new class of inhibitors. These efforts lead to the discovery of benzoxazole 11v, which raised HDLc by 24 mg/dl in our transgenic mouse PD model.

CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.

CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.

CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems ofthe industrialized world In formula I, A-B is an arylamide moiety

COMPOUNDS USEFUL AS A3 ADENOSINE RECEPTOR AGONISTS

Compounds useful as A3 Adenosine Receptor Agonists. Adenosine analogue-type A3 receptor agonists having an N6 substituent of the formula CR20R21CYCLE where CYCLE is a specified heterocycle, e.g. a substituted pyridyl group or a substituted oxazolyl-containing bicyclic ring. 10